RYAM's 2026 Turnaround Plan Highlights Optimism Amid Deep Skepticism and Financial Strain

What happened

RYAM's new CEO Scott Sutton used the Q4 2025 earnings call to announce a 2026 plan focused on restoring positive free cash flow, lifting Cellulose Specialties pricing, and improving EBITDA across the portfolio. This forward-looking narrative, however, masks the harsh reality outlined in DeepValue's report, which notes persistent GAAP losses, declining Adjusted EBITDA guidance for 2025, and a highly leveraged balance sheet with $794M in debt and interest coverage of just 0.05x. The company's equity is tightly coupled to execution risks in a cyclical industry, with minimal margin for error given thin liquidity and recurring non-GAAP adjustments that obscure true financial health. Market skepticism is stark, as the stock trades around $6.39, significantly below a DCF estimate of $32.53, reflecting deep doubts about management's ability to deliver on aggressive targets like over $300M EBITDA by 2027. Despite the CEO's site visits and strategic promises, the gap between ambition and track record remains wide, underscoring the need for tangible progress before investor confidence can improve.

Implication

First, RYAM's high leverage and weak interest coverage heighten refinancing and covenant risks, threatening equity value in adverse scenarios. Second, the guided decline in Adjusted EBITDA from 2024 levels signals ongoing operational challenges that could impede cash flow generation. Third, external factors such as tariff outcomes and competitive pressures in key markets could cap pricing improvements and force further production curtailments. Fourth, the biomaterials pipeline and cost-reduction initiatives, while promising, require significant capital and execution success, which are uncertain given past impairments and volatility. Fifth, until sustained positive free cash flow and a clear deleveraging trend emerge, the stock remains a high-risk speculation rather than a compelling investment, warranting close monitoring rather than new exposure.

Thesis delta

The thesis remains unchanged, reinforcing DeepValue's 'WAIT' stance, as this news does not alter the core risks of high leverage, execution uncertainty, and cyclical pressures. Any shift would require concrete evidence of improved free cash flow and declining leverage, which are not yet demonstrated. Thus, the investment case continues to hinge on monitoring the watch items outlined in the report, with no material upgrade or downgrade warranted at this time.